A Multicenter Cancer Biospecimen Collection Study

Recruiting now

Conditions studied: Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer

In brief

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

Key facts

Study ID

NCT04510129

Run by

Cofactor Genomics, Inc.

People needed

1650

Starts

2020-02-05

Expected to finish

2027-02-01

Last updated by the study team

2025-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must have a disease of interest. Specifically, subject must have one of:
• head and neck squamous cell carcinoma (HNSCC)
• non-small-cell lung cancer (NSCLC)
• small cell lung cancer (SCLC)
• urothelial carcinoma (UCC)
• gastric or gastroesophageal junction adenocarcinoma
• cervical cancer
• esophageal squamous cell carcinoma (ESCC)
• triple-negative breast cancer (TNBC)
• hepatocellular carcinoma (HCC)
• renal cell carcinoma (RCC)
• colorectal cancer (CRC)
• Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1/PD-L1 immunotherapy for treatment of their cancer.
• Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1/PD-L1 immunotherapy.
• Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy.
• Willing to provide electronic informed consent per IRB-approved protocol.
• Able to speak, read, and comprehend English fluently.
• Subject is 18 years of age or older.
• Subjects must have sufficient tissue available to fulfill the specimen requirements of the study.

You may not qualify if…

• Inability or unwillingness to provide informed consent.
• Subject who does/did not have one of the cancers listed above (other histologies).
• Subject has already participated in this trial.

Where it is running

• Curebase — San Francisco, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.